Ffrangio
Payments companies reported to CMS as associated with Ffrangio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ffrangio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ffrangio
These are the largest totals companies reported as associated with Ffrangio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rahul Sharma | Stanford, CA | Interventional Cardiology | $188,631.55 |
| Amir Kaki | Detroit, MI | Interventional Cardiology | $187,715.03 |
| Paul Teirstein | La Jolla, CA | Interventional Cardiology | $88,053.20 |
| Megha Prasad | New York, NY | Cardiovascular Disease | $60,695.51 |
| Shailendra Singh | Allentown, PA | Interventional Cardiology | $53,121.82 |
| Ankitkumar Patel | Glen Ridge, NJ | Interventional Cardiology | $51,524.29 |
| Morton Kern | Orange, CA | Cardiovascular Disease | $44,432.49 |
| Curtiss Stinis | La Jolla, CA | Interventional Cardiology | $43,113.20 |
| Michael Kim | Manhasset, NY | Interventional Cardiology | $38,547.08 |
| Arber Kodra | New York, NY | Interventional Cardiology | $32,659.75 |
Prescribed Ffrangio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.